Login
Neos Therapeutics NASDAQ: NEOS
Neos Therapeutics is focused on developing, manufacturing, and commercializing innovative extended-release products that utilize our proprietary modified-release drug delivery technology platform
| Name | Neos Therapeutics |
| Ticker | NEOS |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Drug Manufacturers -Specialty Pharma |
| Price | 0.66 |
| 52W Low/High | 0.64 / 1.88 |
| Market cap | 33 M |
| 1Y Total Return |
-60.94%
Weak |
| 1Y Volatility |
76.87%
More Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Neos Therapeutics is focused on developing, manufacturing, and commercializing innovative extended-release products that utilize our proprietary modified-release drug delivery technology platform
Details
| Ticker | NEOS |
| Name | Neos Therapeutics |
| ISIN | US64052L1061 |
| CUSIP | |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Drug Manufacturers -Specialty Pharma |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 9/18/20
| Close Price | 0.66 |
| 52W Low/High | 0.64 / 1.88 |
| Market cap | 33 M |
| 1Y Total Return |
-60.94%
Weak |
| 1Y Volatility |
76.87%
More Risk |
| Beta | 1.97 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -30.6% |
| Cash from Op. / Cur. Liabilities | -0.14 |
| Diluted Earnings / Share | -0.38 |
| ROE | - |
| ROIC | - |
| Price / Revenue | 0.5 |
| Price / Book | -2.0 |
| Price / CF | -3.9 |
| Current Ratio | 0.7 |
| Cur.Liabilities / Tot.Liabilities | 0.8 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
62
|
58
|
38
|
17
|
6
|
-
|
|
| Gross Profit |
36
|
32
|
20
|
3
|
-
|
-
|
|
| R&D |
7
|
10
|
8
|
12
|
11
|
-
|
|
| EBITDA |
-7
|
-21
|
-46
|
-68
|
-50
|
-
|
|
| Operating Income |
-11
|
-26
|
-51
|
-71
|
-51
|
-
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
50
|
50
|
29
|
23
|
16
|
-
|
|
| EPS exc. Extra |
-0.38
|
-0.81
|
-2.03
|
-4.42
|
-2.54
|
-
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
63
|
89
|
84
|
118
|
118
|
56
|
|
| Cash, Eq & Invt ShortTerm |
13
|
30
|
28
|
79
|
80
|
26
|
|
| Total Current Assets |
40
|
65
|
60
|
93
|
92
|
30
|
|
| Total Non-Current Assets |
22
|
25
|
24
|
25
|
26
|
26
|
|
| Intangibles |
12
|
14
|
16
|
17
|
16
|
17
|
|
| Total Liabilities |
79
|
91
|
103
|
93
|
77
|
149
|
|
| Total Current Liabilities |
61
|
57
|
56
|
31
|
17
|
7
|
|
| Long Term Debt |
18
|
34
|
46
|
62
|
60
|
142
|
|
| Shareholder equity |
-16
|
-2
|
-19
|
25
|
41
|
-93
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-8
|
-28
|
-52
|
-61
|
-45
|
-
|
|
| Depreciation |
4
|
4
|
3
|
3
|
3
|
-
|
|
| Cash from Investing |
4
|
4
|
10
|
18
|
-42
|
-
|
|
| Capex |
1
|
1
|
2
|
3
|
3
|
-
|
|
| Cash from Financing |
-8
|
31
|
3
|
59
|
103
|
-
|
|
| Stock Issued |
0
|
47
|
4
|
60
|
80
|
-
|
|
| Debt (LT) Issued |
-8
|
-16
|
-1
|
-1
|
23
|
-
|
|
| Free Cash Flow |
1
|
-27
|
-24
|
-43
|
-88
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
0.7
|
1.1
|
1.1
|
3.0
|
5.5
|
4.2
|
|
| Financial Leverage D/E |
-
|
-
|
-
|
2.61
|
1.48
|
-
|
|
| Return on Capital Avg |
-
|
-313.8%
|
-248.9%
|
-157.9%
|
-128.8%
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available